2020 CNS Research Day

**As a result of COVID-19 and the increased need to practice social distancing, our Research Committee has decided to cancel the 2020 CNS Research Day. In an effort to minimize the potential risk to our faculty, staff and learners as well as community members. We are looking forward to planning next year's event.

In 2020, the Department of Clinical Neurological Sciences will be hosting its 17th annual CNS Research Day. The day-long event features a series of poster and oral presentations from our residents, graduate students, PhD candidates and postdoctoral fellows. We will also host a distinguished researcher who will present the keynote address. Attendees of the event are the Department’s faculty, including neurosurgeons, neurologists, affiliated radiologists, pathologists and imaging researchers.

Schedule of Events

7:30 a.m. - Registration and Continental Breakfast

8:00 a.m. - Opening Remarks

8:15 a.m. - Oral Presentations

9:15 a.m. - Refreshment Break and Poster Session #1

10:00 a.m. - Oral Presentations (continued)

12:00 p.m. - Lunch and Poster Viewing

1:00 p.m. - Oral Presentations (continued)

2:15 p.m. - Refreshment Break and Poster Session #2

3:00 p.m. - Oral Presentations (continued)

4:00 p.m. - Keynote Address

4:30 p.m. - Closing Remarks and Awards

Keynote Speaker

Dr. Robert Hart Dr. Hart Headshot
Robert G. Hart, M.D. led the stroke program at the University of Texas Health Sciences Center at San Antonio for 25 years before relocating to McMaster University in 2011. He is Emeritus Professor of Medicine (Neurology) at McMaster University and is a Senior Scientist of Population Health Research Institute. Dr. Hart has long-standing interests in stroke prevention research and clinical trials. He has directed several randomized clinical trials serving as the principal investigator of the NIH/NINDS-sponsored Stroke Prevention in Atrial Fibrillation (SPAF) I, II and III trials (1987-2000) and has participated as a site lead investigator in more than a dozen others. Following completion of the SPAF trials, he was the co-principal investigator of the NIH/NINDS-sponsored Secondary Prevention of Small Subcortical Strokes (SPS3) trials. Between 2013-2018, he was the lead investigator for the large, international NAVIGATE-ESUS testing rivaroxaban in embolic strokes of uncertain source involving 459 sites in 31 countries sponsored by Bayer AG. Between 2000 and 2008, he was a special consultant to the NINDS/NIH Clinical Trials Group. Antithrombotic therapies to prevent stroke in atrial fibrillation (especially novel oral anticoagulants) and intracranial bleeding related to oral anticoagulants are areas of special interest.

Abstract Submission Criteria/Format
*based on the JAMA Structure for Abstract Submission

Importance:	The abstract should begin with a maximum of two sentences explaining the clinical (or other) importance of the study question.
Objective(s):	State the precise objective or study question addressed in the report (e.g. "To determine whether..."). If more than 1 objective is addressed, the main objective should be indicated and only key secondary objectives stated. If a priori hypothesis was tested, it should be stated.
Design and Participants:	Describe the basic design of the study and include the specific study type (e.g. randomized clinical trial, cohort, cross-sectional, etc.) and intervention where applicable. State the clinical disorders, important eligibility criteria, and key socio-demographic features of patients (or other study participants). The number of eligible participants and how they were selected should be provided, including the number approached but who refused or were excluded. For selection procedures, these terms should be used, if appropriate: random sample (where random refers to a formal, randomized selection in which all eligible individuals have a fixed and usually equal chance of selection); population-based sample; referred sample; consecutive sample; volunteer sample; convenience sample. If matching is used for comparison groups, characteristics that are matched should be specified. In follow-up studies, the proportion of participants who completed the study must be indicated.
Results:	Summary demographic information (e.g. characteristics such as sex and age) and the number of study participants should be reported in the first sentence of the Results paragraph. The main outcomes of the study should be reported and quantified, including the final included/analyzed sample. When possible, present numerical results (e.g. absolute numbers and/or rates) with appropriate indicators of uncertainty, such as confidence intervals. Use means and standard deviations (SDs) for normally distributed data and medians and ranges or interquartile ranges (IQRs) for data that are not normally distributed. Avoid solely reporting the results of statistical hypothesis testing, such as P values, which fail to convey important quantitative information. For most studies, P values should follow the reporting of comparisons of absolute numbers or rates and measures of uncertainty (e.g. 0.8%, 95% CI −0.2% to 1.8%; P = .13).
Conclusions and Relevance:	Provide only conclusions of the study that are directly supported by the results. Give equal emphasis to positive and negative findings of equal scientific merit. Also, provide a statement of relevance indicating implications for clinical practice or health policy, avoiding speculation and overgeneralization. The relevance statement may also indicate whether additional study is required before the information should be used in clinical settings.